Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.55 |
| ▸ | CA2 | P00918 | 4/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.54 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.54 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.54 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.54 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MITF | O75030 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6009391 | 0.85 | SCN8A (0.49) | CA1CA2HDAC3HDAC4HDAC1 | |
| SCHEMBL355305 | 0.83 | CHRM2 (0.66) | CA1CA2HDAC3HDAC4HDAC1 | |
| SCHEMBL10045159 | 0.82 | HDAC3 (0.63) | CA1CA2HDAC3HDAC4HDAC1 | |
| SCHEMBL10045164 | 0.82 | HDAC3 (0.63) | CA1CA2HDAC3HDAC4HDAC1 | |
| SCHEMBL10045167 | 0.80 | HDAC3 (0.63) | CA1CA2HDAC3HDAC4HDAC1 | |
| SCHEMBL10045129 | 0.80 | HDAC3 (0.61) | CA1CA2HDAC3HDAC4HDAC1 | |
| SCHEMBL354765 | 0.80 | SLC2A1 (0.46) | CA1CA2EPHX2NR1H4CHRM2 | |
| SCHEMBL6009935 | 0.80 | CHRM2 (0.66) | CA1CA2HDAC3HDAC1HDAC2 | |
| SCHEMBL27941504 | 0.80 | CHRM2 (0.66) | CA1CA2KDM4EKMT2ACHRM2 | |
| SCHEMBL10278319 | 0.79 | GRIA4 (0.43) | CA1CA2EPHX2NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2014-11-06 | — | — | US | disclosed |
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2014-11-06 | — | — | US | disclosed |
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2014-11-06 | — | — | US | disclosed |
| US-8835654-B2 | Method and compositions for treating amyloid-related diseases | BHI LIMITED PARTNERSHIP (CA) | 2014-09-16 | — | — | US | disclosed |
| US-8835654-B2 | Method and compositions for treating amyloid-related diseases | BHI LIMITED PARTNERSHIP (CA) | 2014-09-16 | — | — | US | disclosed |
| US-8835654-B2 | Method and compositions for treating amyloid-related diseases | BHI LIMITED PARTNERSHIP (CA) | 2014-09-16 | — | — | US | disclosed |
| US-20120015911-A1 | METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BELLUS HEALTH INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-20120015911-A1 | METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BELLUS HEALTH INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-20120015911-A1 | METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BELLUS HEALTH INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-8044100-B2 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH INC. (CA) | 2011-10-25 | — | — | US | disclosed |
| US-8044100-B2 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH INC. (CA) | 2011-10-25 | — | — | US | disclosed |
| US-8044100-B2 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH INC. (CA) | 2011-10-25 | — | — | US | disclosed |
| US-20060223855-A1 | reduces or inhibits amyloid fibril formation, organ specific dysfunction (e.g., neurodegeneration), or cellular toxicity | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223855-A1 | reduces or inhibits amyloid fibril formation, organ specific dysfunction (e.g., neurodegeneration), or cellular toxicity | APP, IAPP, BACE1 | CA1 1133/4885CA2 2710/4885HDAC3 4086/4885 |
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | CA1 582/4885CA2 1085/4885HDAC3 3443/4885 |
| US-20120015911-A1 | METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | CA1 670/4885CA2 1405/4885HDAC3 3972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.